دورية أكاديمية
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.
| العنوان: | A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer. |
|---|---|
| المؤلفون: | Yun T; Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Kim HT; Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Han JY; Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Yoon SJ; Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Kim HY; Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Nam BH; Cancer Biostatistics Branch, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Lee JS; Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea. |
| المصدر: | Cancer research and treatment [Cancer Res Treat] 2016 Apr; Vol. 48 (2), pp. 465-72. Date of Electronic Publication: 2015 May 26. |
| نوع المنشور: | Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2005-9256 (Electronic) Linking ISSN: 15982998 NLM ISO Abbreviation: Cancer Res Treat Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Seoul, Korea : The Association, |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Small Cell Lung Carcinoma*/drug therapy , Small Cell Lung Carcinoma*/pathology, Aged ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Paclitaxel |
| مستخلص: | Purpose: Paclitaxel (P) and gemcitabine (G) are clinically synergistic in small cell lung cancer (SCLC). We evaluated the efficacy of PG as a salvage treatment for SCLC patients whose disease progressed after a platinum-containing regimen. Materials and Methods: Eligibility included histologically confirmed SCLC, one dimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and progressive disease after platinum-based chemotherapy. Treatment consisted of P (80 mg/m(2)) and G (1,000 mg/m(2)) on days 1 and 8 of each cycle of 21 days until disease progression. Results: Thirty-three patients seen between December 2005 and February 2009 were selected into this study. Thirty patients (91%) had received irinotecan-platinum, and three had received etoposide-platinum. Sixteen patients (49%) had a treatment-free interval of less than 3 months. The overall response rate was 30.3% (29.4% in sensitive relapse and 31.3% in refractory relapse). The median time to progression was 12.0 weeks and median overall survival (OS) 31.0 weeks, with a 1-year OS rate of 30.3%. Toxicities were moderate and manageable with 18.2% grade (G) 4 neutropenia, 24.2% G3 thrombocytopenia, 6.1% G3 sensory neuropathy, and 3% G3 asthenia. One patient developed febrile neutropenia. Conclusion: Second-line paclitaxel and gemcitabine were well-tolerated and moderately active in SCLC patients previously treated with platinum-based chemotherapy. |
| References: | J Clin Oncol. 2006 Dec 1;24(34):5441-7. (PMID: 17135646) Cancer Chemother Pharmacol. 2001 Aug;48(2):141-4. (PMID: 11561780) Cancer. 2003 May 1;97(9):2242-7. (PMID: 12712478) Br J Cancer. 1998;77(2):347-51. (PMID: 9461009) J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. (PMID: 10655437) Control Clin Trials. 1989 Mar;10(1):1-10. (PMID: 2702835) J Clin Oncol. 1996 Oct;14(10):2785-90. (PMID: 8874340) Oncology. 1996 Mar-Apr;53(2):169-72. (PMID: 8604245) Clin Lung Cancer. 2003 Jan;4(4):229-30. (PMID: 14624711) Anticancer Res. 2006 Jan-Feb;26(1B):777-81. (PMID: 16739353) N Engl J Med. 2002 Jan 10;346(2):85-91. (PMID: 11784874) Clin Med Insights Oncol. 2011;5:223-34. (PMID: 21836818) J Clin Oncol. 2014 Dec 10;32(35):4012-9. (PMID: 25385727) Cancer Chemother Pharmacol. 2003 Apr;51(4):328-36. (PMID: 12721761) Cancer Chemother Pharmacol. 2006 Aug;58(2):203-9. (PMID: 16331497) J Clin Oncol. 2003 Apr 15;21(8):1550-5. (PMID: 12697880) J Clin Oncol. 2007 May 20;25(15):2086-92. (PMID: 17513814) Lung Cancer. 2005 Mar;47(3):413-9. (PMID: 15713525) Clin Cancer Res. 2003 Jan;9(1):143-50. (PMID: 12538462) J Clin Oncol. 1997 May;15(5):2090-6. (PMID: 9164222) Anticancer Res. 2005 Jan-Feb;25(1B):409-14. (PMID: 15816603) Ann Oncol. 2001 Apr;12(4):557-61. (PMID: 11398892) |
| فهرسة مساهمة: | Keywords: Gemcitabine; Paclitaxel; Second-line; Small cell lung carcinoma |
| المشرفين على المادة: | P88XT4IS4D (Paclitaxel) |
| تواريخ الأحداث: | Date Created: 20150606 Date Completed: 20180222 Latest Revision: 20181202 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC4843756 |
| DOI: | 10.4143/crt.2015.061 |
| PMID: | 26044164 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2005-9256 |
|---|---|
| DOI: | 10.4143/crt.2015.061 |